PeerVoice Oncology & Haematology Audio

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025

Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC

Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO

Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients

Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease

Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer